Precision BioSciences, Inc. Common Stock DTIL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T02:33:36.551Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:10:37.430229563Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T02:33:36.178835+00:00
Precision BioSciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.37 | 626.2% | 58.1% | |||
| 25Δ | 5.12 | 559.1% | 50.2% | |||
| 30Δ | 5.88 | 491.9% | 42.3% | |||
| 35Δ | 16.32 | 463.5% | 156.7% | 6.63 | 424.7% | 34.4% |
| 40Δ | 14.19 | 465.1% | 128.6% | 7.38 | 357.6% | 26.4% |
| 45Δ | 13.24 | 491.4% | 118.6% | 7.75 | 328.5% | 22.9% |
| 50Δ | 12.29 | 517.8% | 108.6% | 8.05 | 306.6% | 20.2% |
| 55Δ | 11.34 | 544.2% | 98.6% | 8.36 | 284.7% | 17.5% |
| 60Δ | 10.39 | 570.5% | 88.6% | 8.66 | 262.9% | 14.7% |
| 65Δ | 8.45 | 526.0% | 62.1% | 8.96 | 241.0% | 12.0% |
| 70Δ | 9.26 | 219.1% | 9.3% | |||
| 75Δ | 9.56 | 197.2% | 6.6% | |||
| 80Δ | 4.80 | 295.8% | 9.8% | 9.86 | 175.3% | 3.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.37
- IV
- 626.2%
- B/E move
- 58.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.12
- IV
- 559.1%
- B/E move
- 50.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.88
- IV
- 491.9%
- B/E move
- 42.3%
35Δ
- Pseudo strike
- 16.32
- IV
- 463.5%
- B/E move
- 156.7%
- Pseudo strike
- 6.63
- IV
- 424.7%
- B/E move
- 34.4%
40Δ
- Pseudo strike
- 14.19
- IV
- 465.1%
- B/E move
- 128.6%
- Pseudo strike
- 7.38
- IV
- 357.6%
- B/E move
- 26.4%
45Δ
- Pseudo strike
- 13.24
- IV
- 491.4%
- B/E move
- 118.6%
- Pseudo strike
- 7.75
- IV
- 328.5%
- B/E move
- 22.9%
50Δ
- Pseudo strike
- 12.29
- IV
- 517.8%
- B/E move
- 108.6%
- Pseudo strike
- 8.05
- IV
- 306.6%
- B/E move
- 20.2%
55Δ
- Pseudo strike
- 11.34
- IV
- 544.2%
- B/E move
- 98.6%
- Pseudo strike
- 8.36
- IV
- 284.7%
- B/E move
- 17.5%
60Δ
- Pseudo strike
- 10.39
- IV
- 570.5%
- B/E move
- 88.6%
- Pseudo strike
- 8.66
- IV
- 262.9%
- B/E move
- 14.7%
65Δ
- Pseudo strike
- 8.45
- IV
- 526.0%
- B/E move
- 62.1%
- Pseudo strike
- 8.96
- IV
- 241.0%
- B/E move
- 12.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.26
- IV
- 219.1%
- B/E move
- 9.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.56
- IV
- 197.2%
- B/E move
- 6.6%
80Δ
- Pseudo strike
- 4.80
- IV
- 295.8%
- B/E move
- 9.8%
- Pseudo strike
- 9.86
- IV
- 175.3%
- B/E move
- 3.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 197.13% |
Biotechnology
DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral…
More →ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →ELVN
Description unavailable
More →ENGN
Description unavailable
More →